Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
August 01 2022 - 8:00AM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a
biopharmaceutical company focused on developing a diversified
pipeline of targeted therapies for patients with cancer, today
announced that its Chief Financial Officer, Jeff Trigilio, will
participate in the following investor conferences in August.
- Mr. Trigilio will participate in a fireside chat at the BTIG
Biotechnology Conference 2022 on August 8, 2022 at 1:00 p.m.
EDT
- Mr. Trigilio will deliver a Company presentation at the
Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022
at 3:30 p.m. EDT
A live webcast of the Canaccord Genuity conference presentation
will be available via the Events section of the Company’s investor
relations website at
https://investors.cullinanoncology.com/news-events/events.
Investors interested in scheduling a one-on-one meeting with
Cullinan Oncology’s management should contact their BTIG or
Canaccord Genuity representative.
About Cullinan Oncology Cullinan Oncology, Inc.
(Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating
new standards of care for patients with cancer. We innovate without
borders to find the most promising clinic-ready cancer therapies,
whether from our own discovery efforts or through exceptional
engagement with our academic and industry partners. Anchored in a
deep understanding of immuno-oncology and translational cancer
medicine, we leverage our scientific excellence in small molecules
and biologics to create differentiated ideas, identify unique
targets, and select the optimal modality to develop transformative
therapeutics across cancer indications. Powered by our novel
research model, we push conventional boundaries from candidate
selection to cancer therapeutic, applying rigorous early
experimentation to fast-track only the most promising assets to the
clinic and ultimately commercialization. As a result, our
diversified pipeline is strategically built with assets that
activate the immune system or inhibit key oncogenic drivers across
a wide range of modalities, each with the potential to be the best
or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Contacts: Investor Relations Chad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1 215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024